Drowsiness Leader Optalert owns the Johns Drowsiness Scale and serves as a global standard for objective drowsiness measurement, presenting a compelling value proposition for safety-critical industries seeking reliable fatigue screening.

Industry Partnerships A strong track record with high-profile clients and research partners (BHP Billiton, Vale, NASA, Harvard Medical School, Monash University, University of Queensland) creates compelling case studies for expanding into transport, mining, aerospace, and healthcare sectors.

Blepharometry Advantage Pioneering biomarker discovery linking eyelid movement to brain function positions Optalert to expand into broader neurological assessments such as epilepsy, ADHD, Parkinson’s, and concussion, offering adjacent diagnostic solutions.

Product Ecosystem Recent releases and services (SDK Release 7.0, Drowsiness Detection Validation Service, real-time eyelid measurement systems) indicate a mature product suite suitable for integration by OEMs and third-party monitoring platforms.

Growth Readiness With a revenue range of 1–10 million and an established R&D and regulatory validation profile, Optalert is positioned to scale internationally through channel partnerships, licensing deals, and enterprise deployments.